|
Gardiquimod VacciGrade™
Imidazoquinoline compound
Gardiquimod™ is an imidazoquinoline compound developed and manufactured by InvivoGen. This imidazoquinoline compound is a guanosine derivative and agonist for TLR7. Gardiquimod™ is an effective adjuvant by activating dendritic cells (DCs) and B cells to induce cytokines optimal for Th1 cell immunity, and antibody production.
Gardiquimod™ VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
Gardiquimod™ VacciGrade™ is for research use only, not for use in humans.
Specificity: Th1 response
Working concentration: 10- 100 μg/mouse
Solubility: 1 mg/ml in physiological water |